ADAM17 mediates OSCC development in an orthotopic murine model

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Simabuco, Fernando M ^a,b   Kawahara, Rebeca ^a   Yokoo, Sami ^a   Granato, Daniela C ^a   Miguel, Lucas ^a   Agostini, Michelle ^c   Aragão, Annelize Z B ^a   Domingues, Romênia R ^a   Flores, Isadora L ^a,b   Macedo, Carolina C S ^a,b   Coletta, Ricardo D ^b   Graner, Edgard ^b   Paes Leme, Adriana F ^a  

^a BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MOUTH NEOPLASMS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84893203138     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-24     Document Type: Article

References (50)

1. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
2. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010, 45:146-169. 10.3109/10409231003628015, 2841225, 20184396.
3. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289. 10.1016/j.mam.2008.08.001, 18762209.
4. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009, 15:1140-1144. 10.1158/1078-0432.CCR-08-1585, 19228719.
5. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005, 6:32-43. 10.1038/nrm1548, 15688065.
6. Sheu JJ-C, Hua C-H, Wan L, Lin Y-J, Lai M-T, Tseng H-C, Jinawath N, Tsai M-H, Chang N-W, Lin C-F, Lin C-C, Hsieh L-J, Wang T-L, Shih I-M, Tsai F-J. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009, 69:2568-2576. 10.1158/0008-5472.CAN-08-3199, 19276369.
7. Bonner J, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
8. Huang S, O Sullivan B. Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral y Cir Bucal 2013, 18:e233-e240.
9. Petersen PE. The world oral health report 2003: continuous improvement of oral health in the 21st century-the approach of the WHO global oral health programme. Community Dent Oral Epidemiol 2003, 31(Suppl 1):3-23.
10. Gschwind A, Hart S, Fischer O, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003, 22:2411-2421. 10.1093/emboj/cdg231, 155989, 12743035.
11. Sobral LM, Bufalino A, Lopes M, Graner E, Salo T, Coletta RD. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol 2011, 47:840-846. 10.1016/j.oraloncology.2011.06.011, 21727023.
12. Paes Leme AF, Sherman NE, Smalley DM, Sizukusa LO, Oliveira AK, Menezes MC, Fox JW, Serrano SMT. Hemorrhagic activity of HF3, a snake venom metalloproteinase: insights from the proteomic analysis of mouse skin and blood plasma. J Proteome Res 2012, 11:279-291. 10.1021/pr2006439, 21939285.
13. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2007, 2:1896-1906. 10.1038/nprot.2007.261, 17703201.
14. Aragão AZB, Belloni M, Simabuco FM, Zanetti MR, Yokoo S, Domingues RR, Kawahara R, Pauletti B, Gonçalves A, Agostini M, Graner E, Coletta RD, Fox JW, Leme AFP. Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration. PLoS One 2012, 7:e43521. 10.1371/journal.pone.0043521, 3419706, 22905270.
15. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372. 10.1038/nbt.1511, 19029910.
16. Cox J, Neuhauser N, Michalski A, Scheltema R, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011, 10:1794-1805. 10.1021/pr101065j, 21254760.
17. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, Lang KS, Häussinger D, Wakeham A, Itie-Youten A, Khokha R, Ohashi PS, Blobel CP, Mak TW. iRhom2 Regulation of TACE controls TNF-mediated protection against listeria and responses to LPS. Science 2012, 335:229-232. 10.1126/science.1214448, 22246778.
18. Le Gall SM, Maretzky T, Issuree PD, Niu X-D, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 2010, 123(Pt 22):3913-3922. 2972273, 20980382.
19. Aragão AZB, Nogueira MLC, Granato DC, Simabuco FM, Honorato RV, Hoffman Z, Yokoo S, Laurindo FRM, Squina FM, Zeri ACM, Oliveira PSL, Sherman NE, Paes Leme AF. Identification of novel interaction between ADAM17 (a disintegrin and metalloprotease 17) and thioredoxin-1. J Biol Chem 2012, 287:43071-43082. 10.1074/jbc.M112.364513, 3522302, 23105116.
20. Paes Leme AF, Kitano ES, Furtado MF, Valente RH, Camargo ACM, Ho PL, Fox JW, Serrano SMT. Analysis of the subproteomes of proteinases and heparin-binding toxins of eight bothrops venoms. Proteomics 2009, 9:733-745. 10.1002/pmic.200800484, 19137556.
21. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 2008, 68:1092-1099. 10.1158/0008-5472.CAN-07-2432, 18281484.
22. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong P-M, Rafii S, Reiss K, Blobel CP. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun 2011, 2:229. 3074487, 21407195.
23. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M. ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 2012, 51:150-164. 10.1002/mc.20772, 3234333, 21480393.
24. Das S, Czarnek M, Bzowska M, Me{ogonek}żyk-Kopeć R, Stalińska K, Wyroba B, Sroka J, Jucha J, Deneka D, Stokłosa P, Ogonek J, Swartz MA, Madeja Z, Bereta J. ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One 2012, 7:e50791. 10.1371/journal.pone.0050791, 3519469, 23251384.
25. Lin P, Sun X, Feng T, Zou H, Jiang Y, Liu Z, Zhao D, Yu X. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem 2012, 359:235-243. 10.1007/s11010-011-1018-8, 21837402.
26. Perna AF, Sepe I, Lanza D, Capasso R, Zappavigna S, Capasso G, Caraglia M, Ingrosso D. Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17-dependent TNF-α activation. J Cell Biochem 2013, 114:1536-1548. 10.1002/jcb.24495, 23297114.
27. Rocks N, Estrella C, Paulissen G, Quesada-Calvo F, Gilles C, Guéders MM, Crahay C, Foidart J-M, Gosset P, Noel A, Cataldo DD. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. Cell Prolif 2008, 41:988-1001. 10.1111/j.1365-2184.2008.00557.x, 19040574.
28. Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL. Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2913-2922. 10.1158/1055-9965.EPI-08-0898, 2784191, 19843672.
29. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James H, Edwards DR, Kähäri V-M. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 2010, 16:2022-2035. 10.1158/1078-0432.CCR-09-2525, 20305301.
30. Kornfeld J-W, Meder S, Wohlberg M, Friedrich RE, Rau T, Riethdorf L, Löning T, Pantel K, Riethdorf S. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer 2011, 104:138-145. 10.1038/sj.bjc.6606017, 3039790, 21102583.
31. Hinsley EE, Hunt S, Hunter KD, Whawell SA, Lambert DW. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. Int J Cancer 2012, 130:40-47. 10.1002/ijc.25968, 21491424.
32. Yu C-C, Tsai L-L, Wang M-L, Yu C-H, Lo W-L, Chang Y-C, Chiou G-Y, Chou M-Y, Chiou S-H S-H. miR145 Targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013, 71:3425-3440.
33. M Andrade L, Geraldo JM. Nucleoplasmic calcium buffering sensitizes human squamous cell carcinoma to anticancer therapy. J Cancer Sci Ther 2012, 04:131-139.
34. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094. 10.1038/leu.2011.66, 21494257.
35. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012, 66:105-143. 10.1016/j.phrs.2012.04.005, 22569528.
36. Da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, Bradford CR, Rodrigo JP, Rinaldo A, Hier MP, Kowalski LP. Advances and applications of oral cancer basic research. Oral Oncol 2011, 47:783-791. 10.1016/j.oraloncology.2011.07.004, 21802978.
37. Wang D, Su L, Huang D, Zhang H, Shin DM, Chen ZG. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer 2011, 10:116. 10.1186/1476-4598-10-116, 3192774, 21939503.
38. Guinea-Viniegra J, Zenz R, Scheuch H, Jiménez M, Bakiri L, Petzelbauer P, Wagner EF. Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J Clin Invest 2012, 122:2898-2910. 10.1172/JCI63103, 3408745, 22772468.
39. Baldwin AS. Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol Rev 2012, 246:327-345. 10.1111/j.1600-065X.2012.01095.x, 22435564.
40. Page A, Cascallana JL, Casanova ML, Navarro M, Alameda JP, Pérez P, Bravo A, Ramírez A. IKKβ overexpression leads to pathologic lesions in stratified epithelia and exocrine glands and to tumoral transformation of oral epithelia. Mol Cancer Res 2011, 9:1329-1338. 10.1158/1541-7786.MCR-11-0168, 21821676.
41. Lu K-W, Tsai M-L, Chen J-C, Hsu S-C, Hsia T-C, Lin M-W, Huang A-C, Chang Y-H, Ip S-W, Lu H-F, Chung J-G. Gypenosides inhibited invasion and migration of human tongue cancer SCC4 cells through down-regulation of NFkappaB and matrix metalloproteinase-9. Anticancer Res 2008, 28:1093-1099.
42. Kwon H-K, Hwang J-S, So J-S, Lee C-G, Sahoo A, Ryu J-H, Jeon WK, Ko BS, Im C-R, Lee SH, Park ZY, Im S-H. Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1. BMC Cancer 2010, 10:392. 10.1186/1471-2407-10-392, 2920880, 20653974.
43. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon A-M, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin A-C, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004, 6:97-105. 10.1038/ncb1086, 14743216.
44. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
45. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004, 64:6166-6173. 10.1158/0008-5472.CAN-04-0504, 15342401.
46. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284. 10.1016/j.bbamcr.2006.10.001, 2696318, 17126425.
47. Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu W, Han J, Zheng F, Xie Y, Huang Q. Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer 2012, 11:79. 10.1186/1476-4598-11-79, 3537707, 23083134.
48. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011, 57:123-130. 10.1161/HYPERTENSIONAHA.110.159525, 21079048.
49. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009, 54:575-582. 10.1161/HYPERTENSIONAHA.108.127670, 19581512.
50. Xiao L-J, Lin P, Lin F, Liu X, Qin W, Zou H-F, Guo L, Liu W, Wang S-J, Yu X-G. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 2012, 40:1714-1724.